FDA approves RYTARY for the treatment of Parkinson's Disease
FDA Approves RYTARY for Treatment of Parkinson’s Disease
– Jan 08 2015
The Parkinson’s Disease Foundation (PDF) alerts the community that RYTARYTM, an extended release formulation of carbidopa/levodopa, has been approved by the US Food and Drug Administration (FDA) for the treatment of Parkinson’s disease. The approval was announced today by the drug’s manufacturer, Impax Pharmaceuticals.
Among the medications available to treat Parkinson’s disease, carbidopa/levodopa, often taken as Sinemet(R), remains the gold-standard for easing motor symptoms. But as Parkinson’s disease advances, the drug becomes effective for shorter time periods. This often makes it necessary for people with Parkinson’s disease to take the carbidopa/levodopa four or more times a day to control symptoms.
Even then, people with PD taking the drug experience drops in their levels of levodopa, causing a worsening of motor symptoms as the drug “wears off.”
In recent years, drug manufacturers have tried to develop a formulation of carbidopa/levodopa that would release more slowly over time, and keep levodopa levels more even, thus reducing “off times” for people with Parkinson’s disease. The manufacturer of RYTARYTM states that the drug is designed to reduce off times in people with Parkinson’s disease.
“A new drug for PD is always a cause for celebration. RYTARYTM is formulated to kick in rapidly, then maintain blood levels longer than immediate-release carbidopa/levodopa,” says Kathleen M. Shannon, M.D., Chair of PDF’s Medical Policy Committee and Professor of Neurology at the PDF Research Center at Rush University Medical Center. “This makes it potentially useful for people with Parkinson’s who are having wearing off of drug benefit between doses.”
The manufacturer has announced its expectation for the drug to be available in February 2015 in four strengths. The dose of RYTARYTM must be adjusted carefully as there is not a simple 1:1 relationship between the dose of carbidopa/levodopa and that of RYTARYTM. People with Parkinson’s disease who are interested in RYTARYTM are advised to discuss with their doctors the potential risks and benefits of the drug in comparison with other PD drugs.
PDF welcomes the addition of this new tool for clinicians and people with Parkinson’s disease. For additional information about RYTARYTM, view our video below from Dr. James Beck, Vice President, Scientific Affairs at the Parkinson’s Disease Foundation. For information on other medications for Parkinson’s disease, please contact PDF’s HelpLine at (800) 457-6676 or email@example.com or use our free resources below.
Source Date: Jan 08 2015